Publications by authors named "J Bosq"
Article Synopsis
- - Antibiotics can reduce the effectiveness of PD-1 blockade in cancer treatment, but we still don’t fully understand how they weaken immune responses.
- - The study found that after antibiotics, certain gut bacteria lead to a decrease in MAdCAM-1, promoting regulatory T cells to leave the gut and move into tumors, which negatively impacts immune function.
- - In cancer patients, lower levels of soluble MAdCAM-1 in the blood were associated with poorer outcomes, suggesting that targeting the MAdCAM-1-α4β7 pathway could improve cancer immunotherapy strategies.
As tumors are very heterogeneous, investigating the penetration and concentration of an anticancer drug in different histological regions of a tumor is key to evaluate the efficacy, to improve the pharmacokinetics/pharmacodynamics (PK/PD) relationship evaluation, and to confirm the adequacy of the dose regimen. Quantitative mass spectrometry imaging (QMSI) allows for the determination of the tissue distribution of drugs, metabolites, and biomarkers to support quick and precise evaluation of drug efficacy and safety in a single experiment. QMSI was applied in a preoperative window-of-opportunity (WoO) study of the inhibitor of apoptosis protein antagonist xevinapant (Debio 1143) in patients with resectable squamous cell carcinoma of the head and neck (SCCHN).
View Article and Find Full Text PDFPrimary mediastinal large B-cell lymphoma (PMLBL) is a rare entity predominantly affecting adolescents and young adults. Recently, an international phase II trial in pediatric patients using dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine and prednisone plus rituximab (DA-EPOCH-R) failed to reproduce excellent survival reported in some adult studies. The optimal therapy regimen needs to be determined in this disease.
View Article and Find Full Text PDFArticle Synopsis
- Gut dysbiosis is linked to both intestinal and extraintestinal cancers; however, the relationship between cancer development and changes in the microbiome is still unclear.
- The study found that cancer can cause damage to the ileal mucosa, leading to changes in gut permeability and a rise in Clostridium species, which are associated with dysbiosis.
- Interventions like β-adrenergic receptor blockers or antibiotics helped prevent the detrimental gut changes linked to tumors, suggesting stress ileopathy is an important condition in cancer that needs targeted treatment.
Anti-CD20 monoclonal antibody is a cornerstone therapy for follicular lymphoma. Following anti-CD20 therapy, a potential decrease in CD20 antigen, and therefore a loss of the tumor target might be expected. However, the incidence and clinical significance of CD20 loss on tumor cells in patients with relapsed or refractory follicular lymphoma are unknown.
View Article and Find Full Text PDF